Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core study on SC or IV TCZ and, based on the Investigator's judgment, may continue to benefit from TCZ treatment in this study investigating the SC formulation
Receiving treatment on an outpatient basis
Females of childbearing potential and males with female partners of childbearing potential must agree to use reliable means of contraception as defined by protocol
You may not be if
Premature withdrawal from WA22762 (NCT01194414) or NA25220 (NCT01232569) core studies for any reason
History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
Evidence of serious uncontrolled concomitant disease or disorder
Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
History of or currently active primary or secondary immunodeficiency
Oral corticosteroids at greater than (\>) 10 mg per day prednisone or equivalent, or non-steroidal anti-inflammatory drugs (NSAIDs) above the maximum recommended dose
Intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline
Treatment with any investigational or commercially available biologic disease-modifying anti-rheumatic drug (DMARD) other than TCZ at any time between completion of the core study WA22762 (NCT01194414) or NA25220 (NCT01232569) and enrollment in the long-term extension study
Pregnant or breastfeeding women
History of alcohol, drug, or chemical abuse within 1 year prior to Screening
Clareo Health | A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
